Eli Lilly Says FDA Approves Trijardy for Patients With Type 2 Diabetes
January 27 2020 - 6:31PM
Dow Jones News
By Stephen Nakrosis
Eli Lilly and Co. (LLY) said Monday the U.S. Food and Drug
Administration approved Trijardy to lower blood sugar in adults
with type 2 diabetes.
Lilly said Trijardy XR, which is marketed by Boehringer
Ingelheim Pharmaceuticals, Inc. and Lilly, combines three
medicines--Jardiance, or empagliflozin, Tradjenta, or linagliptin,
and metformin hydrochloride extended release--in one pill.
Trijardy is indicated for use along with diet and exercise to
lower blood sugar.
Trijardy is a once-a-day medication, Lilly said, adding it will
be available in four different dosages.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 27, 2020 18:16 ET (23:16 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Sep 2023 to Sep 2024
